Net Income (Loss) Attributable to Parent of Spero Therapeutics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Spero Therapeutics, Inc. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Spero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $7,382,000, a 57% increase year-over-year.
  • Spero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $43,836,000, a 1343% decline year-over-year.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was $68,566,000, a 401% decline from 2023.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $22,806,000.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $89,800,000, a 15% decline from 2020.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Spero Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $43,836,000 $7,382,000 +$9,765,000 +57% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $53,601,000 $1,700,000 +$16,162,000 +90% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $69,763,000 $13,866,000 -$1,197,000 -9.4% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $68,566,000 $20,888,000 -$72,094,000 -141% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $3,528,000 $17,147,000 -$13,947,000 -436% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $17,475,000 $17,862,000 -$5,962,000 -50% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $23,437,000 $12,669,000 +$631,000 +4.7% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $22,806,000 $51,206,000 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $3,200,000 +$8,500,000 +73% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $11,900,000 +$16,800,000 +59% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $13,300,000 +$19,500,000 +59% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2022 $102,500,000 $11,700,000 +$10,800,000 +48% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $113,300,000 $28,700,000 -$10,100,000 -54% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $103,200,000 $32,800,000 -$13,400,000 -69% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $89,800,000 $29,300,000 -$10,700,000 -58% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2022 2021 FY
Q3 2021 $79,100,000 $22,500,000 -$3,600,000 -19% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $75,500,000 $18,600,000 -$1,100,000 -6.3% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $74,400,000 $19,400,000 +$3,900,000 +17% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $78,300,000 $18,600,000 +$6,300,000 +25% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $84,600,000 $18,900,000 -$1,200,000 -6.8% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $83,400,000 $17,500,000 -$4,300,000 -33% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $79,100,000 $23,300,000 -$18,200,000 -357% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $60,900,000 $24,900,000 -$14,263,000 -134% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q3 2019 $46,637,000 $17,700,000 -$7,237,000 -69% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $39,400,000 $13,200,000 -$3,244,000 -33% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $36,156,000 $5,100,000 +$5,544,000 +52% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $41,700,000 $10,637,000 +$3,225,000 +23% 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
Q3 2018 $44,925,000 $10,463,000 -$627,000 -6.4% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2018 2018 Q3
Q2 2018 $44,298,000 $9,956,000 -$787,000 -8.6% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 $43,511,000 $10,644,000 -$4,768,000 -81% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2018 2018 Q1
Q4 2017 $38,743,000 $13,862,000 -$6,651,000 -92% 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q3 2017 $32,092,000 $9,836,000 -$3,520,000 -56% 01 Jul 2017 30 Sep 2017 10-K 14 Mar 2019 2018 FY
Q2 2017 $28,572,000 $9,169,000 -$3,110,000 -51% 01 Apr 2017 30 Jun 2017 10-K 14 Mar 2019 2018 FY
Q1 2017 $25,462,000 $5,876,000 +$29,000 +0.49% 01 Jan 2017 31 Mar 2017 10-K 14 Mar 2019 2018 FY
Q4 2016 $25,491,000 $7,211,000 01 Oct 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
Q3 2016 $6,316,000 01 Jul 2016 30 Sep 2016 10-K 02 Apr 2018 2017 FY
Q2 2016 $6,059,000 01 Apr 2016 30 Jun 2016 10-K 02 Apr 2018 2017 FY
Q1 2016 $5,905,000 01 Jan 2016 31 Mar 2016 10-K 02 Apr 2018 2017 FY

Spero Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $68,566,000 -$91,372,000 -401% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $22,806,000 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2021 $89,800,000 -$11,500,000 -15% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2022 2021 FY
2020 $78,300,000 -$17,400,000 -29% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $60,900,000 -$19,200,000 -46% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $41,700,000 -$2,957,000 -7.6% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
2017 $38,743,000 -$13,252,000 -52% 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
2016 $25,491,000 -$15,291,000 -150% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
2015 $10,200,000 01 Jan 2015 31 Dec 2015 10-Q 09 Aug 2018 2018 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.